⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10500575 | 0.84 | — | — | |
| SCHEMBL10628314 | 0.79 | — | — | |
| SCHEMBL833603 | 0.77 | — | — | |
| SCHEMBL1218125 | 0.77 | — | — | |
| SCHEMBL4297595 | 0.74 | — | — | |
| SCHEMBL9131970 | 0.74 | — | — | |
| SCHEMBL3248530 | 0.74 | — | — | |
| SCHEMBL1022556 | 0.74 | — | — | |
| SCHEMBL3242435 | 0.74 | — | — | |
| SCHEMBL1345524 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284195-A | Preparation method of fulvestrant | 湖南欧亚药业有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-116284195-A | Preparation method of fulvestrant | 湖南欧亚药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116284195-A | Preparation method of fulvestrant | 湖南欧亚药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-2350111-A1 | PROCESSES AND INTERMEDIATES FOR THE PRODUCTION OF FULVESTRANT | Synthon B.V. (NL) | 2011-08-03 | — | — | EP | disclosed |
| US-20100105934-A1 | FULVESTRANT INTERMEDIATE | SYNTHON BV (NL) | 2010-04-29 | — | — | US | disclosed |
| WO-2010043404-A1 | PROCESSES AND INTERMEDIATES FOR THE PRODUCTION OF FULVESTRANT | SYNTHON B.V. (NL) | 2010-04-22 | — | — | WO | disclosed |
| EP-0346014-A1 | Therapeutic product for the treatment of peri- or postmenopausal conditions | ZENECA LIMITED (GB) | 1989-12-13 | — | — | EP | disclosed |